Leonardo Jaimes, MD

All articles by Leonardo Jaimes, MD

• FDA approves new liquid form of imatinib to treat some forms of SM

  Imatinib is a treatment for patients with aggressive SM without the KIT D816V mutation or having unknown KIT mutational status.

• Study confirms that KIT-inhibitor therapy improves prognosis in advanced SM

  A new prognostic score confirmed that KIT Inhibitors improve outcomes in patients with advanced systemic mastocytosis (SM).

• New predictive model distinguishes indolent SM from advanced SM

  A new model accurately distinguished between advanced and indolent systemic mastocytosis using blood sample parameters.

• Undiagnosed SM leads to hemorrhage in anaphylaxis case

  Undiagnosed systemic mastocytosis (SM) led to bleeding complications in a patient with a peanut allergy reaction.

• SM anaphylaxis from food, drugs not as common as thought: study

  The study results challenge recommendations that people with systemic mastocytosis should avoid certain food and drugs entirely.

• It took more than a decade to diagnose indolent SM in a woman with chronic pain

  The woman lived with abdominal pain for more than a decade before receiving a diagnosis of indolent systemic mastocytosis.

• Experts find several treatments effective in SM-related osteoporosis

  Zoledronic acid, bisphosphonates, IFN-alpha and denosumab appear to prevent fractures and increase BMD in SM patients with osteoporosis.

• Lipid-lowering medications could increase anaphylaxis risk

  Lipid-lowering medications (LLMs) may increase the risk of severe anaphylactic reactions, which would greatly affect patients with SM.

• Patients report SM has a significant effect on their daily lives

  Indolent systemic mastocytosis (ISM) appears to significantly affect activities of daily living in over 50% of patients.

• Avapritinib shows promise in SM in small study

  A new study detailed cellular and other changes resulting from avapritinib therapy for systemic mastocytosis.